Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have given a buy recommendation and […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,540,000 shares, a growth of 6.8% from the April 15th total of 4,250,000 shares. Based on an average daily volume of 830,500 shares, […]
Blueprint Medicines (NASDAQ:BPMC) Upgraded to Market Perform by SVB Leerink tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $107.56 and last traded at $107.00, with a volume of 391291 shares. The stock had previously closed at $94.86. Wall Street Analyst Weigh In A number of brokerages […]